Trelegy ellipta and Ranexa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Trelegy ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate) and Ranexa (ranolazine). Common drug interactions include headache among females and cough among males.

The phase IV clinical study analyzes what interactions people have when they take Trelegy ellipta and Ranexa. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Trelegy ellipta?

Trelegy ellipta has active ingredients of fluticasone furoate; umeclidinium bromide; vilanterol trifenatate. eHealthMe is studying from 28,101 Trelegy ellipta users. Check the latest studies of Trelegy ellipta.

What is Ranexa?

Ranexa has active ingredients of ranolazine. It is often used in angina. eHealthMe is studying from 11,758 Ranexa users. Check the latest studies of Ranexa.

On Jul, 13, 2026

16 people who take Trelegy ellipta and Ranexa together, and have interactions are studied.

Trelegy ellipta and Ranexa drug interactions.

What are the common drug interactions of Trelegy Ellipta and Ranexa, by gender? *:

female:

Headache (pain in head)
Malaise (a feeling of general discomfort or uneasiness)
Nausea (feeling of having an urge to vomit)
Adrenal insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids)
Asthenia (weakness)
Asthma
Atrioventricular block (heart block)
Back pain
Blood pressure decreased
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)

male:

Cough
Dyspnoea (difficult or laboured respiration)
Bronchitis chronic (inflammation of the mucous membrane in the bronchial tubes- chronic)
Cardiac disorder
Chills (felling of cold)
Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
Coronary artery disease (plaque building up along the inner walls of the arteries of the heart, which narrows the arteries and restricts blood flow to the heart)
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs)
Leukocytosis (increased white blood cells)
Lung neoplasm malignant (cancer tumour of lung)

What are the common drug interactions of Trelegy Ellipta and Ranexa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Ankle fracture
Anxiety
Bacterial infection
Depression
Diarrhoea
Disability
Emotional distress
Fungal infection
Intervertebral disc degeneration (spinal disc degeneration)

60+:

Headache (pain in head)
Malaise (a feeling of general discomfort or uneasiness)
Blood pressure decreased
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Cardiac failure congestive
Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Drug hypersensitivity
Ear infection
Infection
Infusion site erythema (reddening of the skin at infusion site)

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 3 people, 18.75%
Primary Immunodeficiency Syndrome: 3 people, 18.75%
Hypersensitivity: 3 people, 18.75%
Chest Pain: 2 people, 12.50%
Percutaneous Coronary Intervention: 2 people, 12.50%
Pain: 2 people, 12.50%
Hiv Infection: 2 people, 12.50%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 6.25%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 6.25%
Dyspnea (difficult or laboured breathing): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Trelegy ellipta and Ranexa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously